Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
Biostrata Ltd on behalf of Thermo
RANDOX LABORATORIES

High-Tech Blood Test Predicts Premature Birth Risk

By Labmedica International staff writers
Posted on 27 Feb 2013
A blood test that predicts preterm birth harvests exosomes from a blood sample and looks for a specific biomarker fingerprint that indicates a high risk for preterm birth, even in women with no known risk factors.

NX PharmaGen (Louisville, KT, USA) has conducted early studies with maternal serum samples using its NeXosome Preterm Birth Assay. Two cohorts were balanced for age and subjects were asymptomatic with no known risk factors, such as hypertension, twins, or gestational diabetes. The average age was 28. In the study, a preterm birth was before 34 weeks and after 37 weeks was full-term.

As early as 15 weeks, the test could detect a risk for preterm birth. NX PharmaGen’s initial human studies also suggest the test could be used for early detection, sub-typing/staging, drug receptor presence/absence, and recurrence monitoring for cancer, including lung cancer, ovarian cancer, and brain cancer.

“If you harvest exosomes and open them up and look at their content, the protein content of a term pregnancy looks very different from a preterm pregnancy,” commented Brian Brohman, co-founder and chief business officer of NX Pharmagen.

The initial benefit of the NeXosome Preterm Birth Assay will allow doctors to move a patient from normal OBGYN care to a fetal medicine specialist.

“This is a tool to tell doctors where they should be spending extra time,” Brian Brohman said. “If you can extend the pregnancy on knowledge of a risk, you can save lots of money.”

Next steps for NX PharmaGen are assay optimization and validation. Brian Brohman said that it is too early to know which regulatory path the company will take: Clinical Laboratory Improvement Amendments a laboratory-developed test (CLIA LDT) and an US Food and Drug Administration (FDA; Silver Spring, MD, USA) approval.

The company is seeking patents on the biomarker pattern that indicates a high risk of premature birth and the method of harvesting exosomes from a blood sample.

Related Links:

NX PharmaGen




KARL HECHT GMBH & CO KG
CELLAVISION AB
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: Thin, lightweight, and flexible materials integrate cellulose paper and flexible polyester films as new diagnostic tools to detect biological agents in whole blood, serum, and peritoneal fluid (Photo courtesy of Florida Atlantic University).

Next Generation of Rapid Diagnostic Assays Will Combine Disposable Test Materials with Smartphone Applications

The new generation of rapid diagnostic tests will reflect advances in both materials sciences and instant communications via the Internet and social media. Current diagnostic assays commonly require... Read more

Microbiology

view channel
Image: The Mini-FLOTAC device for examining stool samples for helminths (Photo courtesy of Public Health Laboratory Ivo de Carneri).

Device Diagnostics of Fixed Soil-Transmitted Helminth Infection Assessed

Kato-Katz is a widely used method for the diagnosis of soil-transmitted helminth infection, but fecal samples cannot be preserved, and hence, should be processed on the day of collection and examined under... Read more

Industry News

view channel
Image: In a new collaboration, Abbott will be the exclusive distributor of Sekisui\'s new CP3000 coagulation instrument in various regions, enabling Abbott to provide coagulation testing solutions with the CP3000, a high-throughput system with a compact footprint (Image courtesy of Abbott).

Partnership to Offer New Coagulation Testing Solutions Worldwide

Abbott (Abbott Park, IL, USA) and Sekisui Diagnostics LLC (Lexington, MA, USA), a sister company of Sekisui Medical (SMD; Tokyo, Japan ), have entered an agreement to offer new coagulation testing solutions... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.